Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 11 | ECE2006 | Next issue

8th European Congress of Endocrinology incorporating the British Endocrine Societies

Oral Communications

Calcium and bone OC49 Novartis Oncology Young Investigator Award

ea0011oc49 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

The A990G polymorphism of calcium sensing receptor gene (CASR) is associated with nephrolithiasis in patients with primary hyperparathyroidism (PHPT)

Eller-Vainicher C , Filopanti M , Vezzoli G , Soldati L , Saeli P , Beck-PEccoz P , Spada A , Corbetta S

Primary HPT shows a great variability in its clinical course and severity, which might be related to polymorphic variants of the CASR gene. The aim of the study was to evaluate the frequency of two known CASR single nucleotide polymorphisms (SNPs), i.e. G/T at codon 986 and G/A at codon 990, in a homogenous North-Italian cohort of PHPT patients compared with a sex and age matched healthy population and the possible correlation of these CASR gene variants with the clinical and ...

ea0011oc50 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

Congenitally hypothyroid mice with (Pax8−/−) or without (hyt/hyt) functional TSH receptors (TSHR) display equivalent skeletal phenotypes

Williams GR , Swinhoe R , Murphy E , Williams AJ , Costagliola S , Vassart G , Howell PGT , Boyde A , Flamant F , Samarut J , Weiss R , Refetoff S , Bassett JHD

Studies of TSHR−/− mice suggest that TSH inhibits bone turnover, but these mice have congenital hypothyroidism and the actions of TSH cannot be separated from effects of thyroid hormone deficiency. We characterised skeletal development in hyt/hyt mice, which have a point mutation in the Tshr gene, and Pax8−/− mice with thyroid gland agenesis. Hyt/hyt mice have a 100-fold increase in TSH but inactive TSHRs, whereas Pax8&...

ea0011oc51 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

TSH receptor action in osteoblasts and osteoclasts in vitro

Murphy E , Williams AJ , Galliford TM , Costagliola S , Vassart G , Bassett JHD , Williams GR

Recent studies suggest TSH inhibits bone remodeling, indicating that TSH deficiency rather than thyroid hormone excess could cause bone loss in thyrotoxicosis. The findings predict that TSH receptor (TSHR) stimulating antibodies (TSHRAb) should inhibit bone turnover, whereas Graves’ disease patients exhibit high bone turnover with increased fracture susceptibility. We characterized TSH-action in primary human and mouse osteoblasts and osteoclasts, and explored whether a p...

ea0011oc52 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

In acromegaly bone mineral density depends on gonadal function

Kochman M , Zgliczynski W , Misiorowski W , Zdunowski P , Papierska L , Zgliczynski S

The aim of the study was to evaluate factors determining bone mineral density (BMD) and serum concentrations of osteocalcin (OC) and carboxyterminal telopeptide of type I collagen (ICTP) in acromegaly. Material consisted of 121 patients with active acromegaly, aged 23–80 years. In the whole group BMD, assessed by DXA, was: 0.35±0.15 at L2–L4, 0.60±0.11 at femoral neck, 0.05±0.12 at Ward’s triangle and 0.59±0.13 at trocha...

ea0011oc53 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

Bone involvement in patients with adrenal incidentalomas: role of subclinical hypercortisolism

Chiodini I , Coletti F , Epaminonda P , Di Lembo S , Morelli V , Masserini B , Adda G , Arosio M

Previous studies suggest that in patients with adrenal incidentalomas (AI) subclinical hypercortisolism (SH) exerts a deleterious effect on bone mineral density (BMD), but scarce data are available about vertebral fractures. We evaluate BMD and prevalence of vertebral fractures in a sample of AI subjects with and without SH.Forty-seven consecutive AI inpatients were evaluated (17M, 30F). The patients were subdivided into two groups: with or without subcl...

ea0011oc54 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

Adult mice harbouring a dominant negative R384C mutation of TRalpha1 have a marked increase in trabecular bone and micro-mineralisation density

Bassett JHD , Nordstrom K , Vennstrom B , Howell PGT , Boyde A , Williams GR

T3-receptor alpha (TRa) is the predominant TR isoform in bone. To investigate its function, we analysed mice harbouring a dominant negative R384C mutation in TRa1 (TRa1m/+). The homozygous TRa1m/m mutation is lethal whereas heterozygotes are euthyroid displaying only transient postnatal hypothyroidism. Critically, dominant negative activity of the mutation is overcome by a 10-fold increase in T3, which is achieved by crossing TRa1m/+ mutants wi...

ea0011oc55 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

Thyroid hormones stimulate osteoblast differentiation but inhibit mineralization of bone nodules in vitro

Williams AJ , Barnard JC , Bassett JHD , Williams GR

Thyroid hormones stimulate bone formation and linear growth in children. Paradoxically, childhood thyrotoxicosis causes short stature and craniosynostosis due to early closure of the growth plates and skull sutures. In adults, however, thyroid hormone excess increases bone turnover and results in progressive bone loss and osteoporosis. Activating mutations of fibroblast growth factor receptor-3 (FGFR3) cause achondroplastic dwarfism and we have shown that T3 augments FGFR sign...

ea0011oc56 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

The Scandinavian investigation of primary hyperparathyroidism (pHPT) – end of inclusion and preliminary results

Bollerslev JB , Jansson SJ , Mollerup CLM , Nordenström JN , Lungren EL , Tørring OT , Franco CF , Varhaug JEV , Isaksen GAI , Rosen TR

Background: From 1999 to the end of June 2005, 186 patients (26 men) with truly asymptomatic pHPT based on the NIH 1990 criteria were included at 11 centres in Scandinavia. The mean age at inclusion was 63.2±7.8 (S.D.) years. After informed consent the patients were randomised to operation (93) or medical observation (94), in order to investigate the effect of operation on Quality of Life and co-morbidity. At present, 159 patients are ongoing, 3 dead, and 2...